News
EIGRQ
10.20
+2.00%
0.20
Amylyx inks deal to buy Eiger’s GLP-1 targeting drug
Seeking Alpha · 1d ago
Weekly Report: what happened at EIGRQ last week (0610-0614)?
Weekly Report · 6d ago
Weekly Report: what happened at EIGRQ last week (0603-0607)?
Weekly Report · 06/10 10:43
Weekly Report: what happened at EIGRQ last week (0527-0531)?
Weekly Report · 06/03 10:45
Eiger BioPharmaceuticals Cautions Investors Amid Bankruptcy
TipRanks · 05/28 12:44
Weekly Report: what happened at EIGRQ last week (0520-0524)?
Weekly Report · 05/27 10:49
Weekly Report: what happened at EIGRQ last week (0513-0517)?
Weekly Report · 05/20 10:44
Weekly Report: what happened at EIGRQ last week (0506-0510)?
Weekly Report · 05/13 10:52
Weekly Report: what happened at EIGRQ last week (0429-0503)?
Weekly Report · 05/06 10:57
Press Release: Sentynl Therapeutics Announces -2-
The Progeria Research Foundation (PRF) was established in 1999 by the family of Sam Berns. PRF is the only non-profit dedicated to finding treatments and the cure for Progera and its aging-related conditions. Eiger's securityholders are cautioned that trading in its securities is highly speculative and poses substantial risks.
Dow Jones · 05/03 21:00
Press Release: Sentynl Therapeutics Announces Global Acquisition of Zokinvy(R) (Lonafarnib) for Treatment of Hutchinson-Gilford Progeria Syndrome from Eiger BioPharmaceuticals
Sentynl Therapeutics Announces Global Acquisition of Zokinvy(R) for Treatment of Hutchinson-Gilford Progeria Syndrome from Eiger BioPharmaceuticals in May 2024. Zokinyvy is approved in the U.S. For the treatment of progeria, a collection of ultra-rare, fatal, genetic premature aging diseases.
Dow Jones · 05/03 21:00
Eiger Biopharmaceuticals CFO Exits Amid Bankruptcy Reorganization
TipRanks · 05/02 20:42
Weekly Report: what happened at EIGRQ last week (0422-0426)?
Weekly Report · 04/29 11:02
Weekly Report: what happened at EIGRQ last week (0415-0419)?
Weekly Report · 04/22 10:54
Weekly Report: what happened at EIGRQ last week (0408-0412)?
Weekly Report · 04/15 10:47
*News On Eiger BioPharmaceuticals Inc. (EIGR) Now Under EIGRQ
Dow Jones · 04/11 21:08
Eiger BioPharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
Eiger BioPharmaceuticals Inc reports results for the quarter ended in December. Revenue rose 41.1% to $3.80 million from a year ago. The company reported a quarterly adjusted loss of $49.39 per share. Shares have fallen 57.8% this quarter and 68.7% this year.
Reuters · 04/09 18:42
Eiger BioPharmaceuticals, Inc. Annual Report for Fiscal Year Ended December 31, 2023
Press release · 04/08 23:41
Weekly Report: what happened at EIGR last week (0401-0405)?
Weekly Report · 04/08 10:51
Eiger BioPharmaceuticals Inc <EIGR.OQ> expected to post a loss of $7.50 a share - Earnings Preview
Eiger BioPharmaceuticals Inc expected to post a loss of $7.50 a share. The company is expected to report a 140.3% increase in quarterly revenue to $6.479 million. The one available analyst rating on the shares is 'strong buy'
Reuters · 04/05 20:06
More
Webull provides a variety of real-time EIGRQ stock news. You can receive the latest news about Eiger Biopharma through multiple platforms. This information may help you make smarter investment decisions.
About EIGRQ
Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development of therapies for hepatitis delta virus (HDV) and other serious rare diseases. The Eiger HDV platform includes two therapies in phase III that target critical host processes involved in viral replication. Its clinical product candidates include Lonafarnib (LNF) for HDV, Peginterferon Lambda (lambda) for HDV and Covid-19, Avexitide in Congenital Hyperinsulinism (HI) and Avexitide in Post-Bariatric Hypoglycemia (PBH). Zokinvy (lonafarnib) for Hutchinson-Gilford progeria syndrome (HGPS) and Processing-Deficient Progeroid Laminopathies (PL) is its approved product. LNF is an orally bioavailable, farnesylation inhibitor in a phase III clinical trial for HDV infection and is its lead program. Lambda is its second program in clinical development for HDV and Covid-19, which is in phase III. Zokinvy is used to reduce the risk of mortality in HGPS and to treat processing-deficient PL.